SCHEMBL5218921

SCHEMBL5218921

CCN(CC)C[C@@H]1CCCN1/C=C/C(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.56
NPC1 O15118 2/20 0.56
USP2 O75604 1/20 0.56
MAPK1 P28482 1/20 0.56
MAOB P27338 1/20 0.49
KDM2B Q8NHM5 1/20 0.44
ABCG2 Q9UNQ0 3/20 0.44
ACHE P22303 1/20 0.42
KDM4E B2RXH2 3/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.42
ACKR3 P25106 3/20 0.42
TNFRSF1A P19438 2/20 0.41
ABCB1 P08183 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217326 0.83 MAPT (0.61) MAPTALDH1A1LMNANPC1USP2
SCHEMBL5958480 0.82 MAPT (0.63) MAPTALDH1A1LMNANPC1USP2
SCHEMBL5225106 0.79 HRH3 (0.48) LMNAMAOBKDM2BPOLB
SCHEMBL5218925 0.73 KMT2A (0.56) ALDH1A1MAOBACHEKDM4EKMT2A
SCHEMBL5221318 0.69 HRH3 (0.52) MAPTALDH1A1LMNAUSP2KDM2B
SCHEMBL5224167 0.68 HRH3 (0.51) MAPTALDH1A1LMNANPC1USP2
SCHEMBL5219025 0.68 HRH3 (0.52) MAPTALDH1A1LMNANPC1MAPK1
SCHEMBL5223521 0.67 HRH3 (0.49) MAPTALDH1A1LMNAUSP2KDM2B
SCHEMBL9047464 0.67 MAPT (0.61) MAPTALDH1A1LMNANPC1USP2
SCHEMBL5224436 0.65 ABCG2 (0.47) MAPTALDH1A1LMNANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474419-B1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK AS (DK) 2007-09-05 EP disclosed
US-7101898-B2 For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder NOVO NORDISK A/S (DK) 2006-09-05 US disclosed
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HIGH POINT PHARMACEUTICALS, LLC 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HRH3, HRH2, HRH4 MAPT 3405/4885ALDH1A1 2049/4885LMNA 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.